In-vitro assays of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody

Journal of Biomedical Materials Research - Part A

Volumn 83, Issue 3, 2007, Pages 861-867

  Yin, Tieying ^a   Wang, Guixue ^a   Ruan, Changgeng ^b   Guzman, Randolph ^c   Guidoin, Robert ^d,e  

^a CHONGQING UNIVERSITY   (China)

^b SUZHOU UNIVERSITY   (China)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

Drug eluting stent; L polylactic acid coating; Monoclonal antibody; Platelet glycoprotein IIb IIIa; Stent

Indexed keywords

DRUG-ELUTING STENT; L-POLYLACTIC ACID COATING; MONOCLONAL ANTIBODY; PLATELET GLYCOPROTEIN IIB; STENT;

BIOCOMPATIBILITY; BLOOD; ORGANIC COATINGS; TISSUE;

ANTIBODIES;

MONOCLONAL ANTIBODY; PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR MONOCLONAL ANTIBODY; POLYMER; SZ 262; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD COMPATIBILITY; BLOOD FLOW; COMPARATIVE STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; IMMUNOFLUORESCENCE; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR PATENCY;

ALLOYS; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; LACTIC ACID; MATERIALS TESTING; MICE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMERS; THROMBOSIS;

EID: 36048981221     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31369     Document Type: Article

References (59)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.
3. Gershlick AH. Treating atherosclerosis: Local drug delivery from laboratory studies to clinical trial. Atherosclerosis 2002;160:259-271.
4. Eeckhout E, Wijns W, Meier B, Goy JJ. Indications for intracoronary stent placement: The European view. Working Group on Coronary Crculation of the European Society of Cardiology. Eur Heart J 1999;20:1014-1019.
5. Edelman RR, Rogers C. Pathobiological responses to stenting. Am J Cardiol 1998;81:4E-6E.
6. Nath FC, Muller DW, Ellis SG, Rosenschein U, Chapekis A, Quain L, Zimmerman C, Topol EJ. Thrombosis of a flexible coil coronary stent: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1993;21:622-627.
7. Foley JB, Brown RI, Penn IM. Thrombosis and restonosis after stenting in failed angioplasty: Comparison with elective stenting. Am Heart J 1994;128:12-20.
8. Liu MW, Voorhees WD III, Agrawal S, Dean LS, Roubin GS. Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: A Cook registry study. Am Heart J 1995;140:8-13.
9. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P. Intracoronary stenting without coumadin: One month results of a French multicenter study. Cathet Cardiovasc Diagn 1995;35:1-7.
10. Hasdai D, Garrat KN, Holmes DR Jr., Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996;28:361-367.
11. Serruys P, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M. Benestent study group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients coronary artery disease. N Engl J Med 1994;331:489-495.
12. Wong SC, Baim DS, Schatz RA, Teirstein PS, King SB III, Curry RC Jr, Heuser RR, Ellis SG, Cleman MW, Overlie P, Hirshfeld JW, Walker CM, Litvak F, Fish D, Brinker JA, Buchbinder M, Goldberg S, Chuang YC, Leon MB. The Palmaz-Schatz Stent Study Group. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. J Am Coll Cardiol 1995;26:704-712.
13. Schwartz RS, Murphy JG, Edwards WD, Holmes DR. Bioabsorbable drug-eluting, intracoronary stents: Design and future applications. In: Sigwart U, Frank GI, editotrs. Coronary Stents. Berlin, Germany: Springer-Verlag; 1992. p 135-154.
14. Lambert TL, Dev V, Rechavia E, Forrester JS, Litvack F, Eigler NL. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin. Circulation 1994;90:1003-1011.
15. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997;349:1429-1435.
16. The EPIC Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
17. The EPIC Investigators. Long term protection from myocardial ischaemic events in a randomized trial of brief integrin beta 3 blockade with percutaneous coronary intervention. J Am Med Assoc 1997;278:479-484.
18. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade and low-dose heparin during percutaneous coronary revascularization. New Engl J Med 1997;336:1689-1696.
19. R) in high-risk diabetic patients undergoing percutaneous coronary intervention. Korean J Intern Med 2003;18:129-137.
20. R) coated stent in patients with coronary artery disease. Korean J Intern Med 2004;19:220-229.
21. Roederer M. Conjugation of monoclonal antibodies. (August, 2004). http://www.drmr.com/abcon/.
22. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997;35:2-3.
23. Xi TF, Wang CR, Lei XH, Tian WH.Deformation and classification of the adhesive platelets on the surface of biomaterials. The third World Biomaterials Congress, Kyoto, Japan, 1988. p 315-316.
24. Xi TF, Wang CR, Lei XH, Tian WH. Studies on shape variation and classification of platelets adhered upon biomaterial surfaces (in Chinese). Beijns J Biomed Eng 1990;9:149-158.
25. Xi TF, Zhang JC, Tian WH, Wang CR, Lei XH, Wai HY, Ruan CG. New method to quantitate platelets adhered on biomaterials using monocloral antibodies to human platelet membrane glycoprotein SZ-21. Biomater Artif Cells Artif Organs 1990;18:423-435.
26. Ko TM, Lin JC, Cooper SL. Surface characterization and platelet adhesion studies of plasma-sulphonated polyethylene. Biomaterials 1993;14:657-664.
27. Huang J. Investigation of biocompatibility of polyethersulfone and sulfonated polyethersulfone used as blood purification membrances (in Chinese). PhD Dissertation, Sichuan University, 1999.
28. Fischell TA. Polymer coatings for stents. Can we judge a stent by its cover? Circulation 1996;94:1494-1495.
29. Van der Giessen WJ, Lincroft AM, Schwartz RS, Van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
30. Vert M. Lactic acid-based bioresorbable polumers: Properties and traps Med J Malaysia 2004;59 (Suppl B):B73-B74.
31. Bertrand OF, Sipehia R, Mongrain R, Rodés J, Tardif JC, Bilodeau L, Côté G, Bourassa MG. Biocompatibility aspect of new stent technology. J Am Coll Cardiol 1998;32:562-571.
32. Agrawal CM, Hass KF, Leopold DA, Clark HG. Evaluation of poly (L-lactic acid) as a material for intravascular polymeric stents. Biomaterials 1992;13:176-182.
33. Vert M, Schwach G, Engel R,Coudane J. Something new in the field of PLA/GA bioresorbable polymers. J Control Release 1998;53:85-92.
34. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP. Biodegradation and brain tissue reaction to poly (D,L- lactide-co-glycolide) microspheres. Biomaterials 1993;14:470-478.
35. Donsi G, Reverchon E. Micronization by means of supercritical fluids: Possibilities of application to pharmaceutical field. Pharm Acta Helv 1991;66:170-173.
36. Merloz PH, Mingelde R, Schelp C, Lavaste F, Huet-Olivier J, Faure C, Butel J. Étude du comportement in-vitro des matériaux biorésorbables en polymère d'acide lactique. Rev Chir Orthop 1995;81:433-444.
37. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori T, Tsuji T, Motohara S, Uehata M. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
38. Costa MA, Foley DP, Serruys PW. Restenosis: The problem and how to deal with it. In: Grech ED, Ramsdale DR, editors. Practical Intervention Cardiology, 2nd ed. London: Martin Dunitz; 2002. p 279-294.
39. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg AL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
40. Lablanche JM, McFadden EP, Bonnet JL, Grollier G, Danchin N, Bedossa M, Leclecq C, Vahanian A, Bauters C Van Belle E, Bertrand MC. Combined antiplatelet therapy with ticlopidine and aspirin.A simplified approach to coronary stent management. Eur Heart J 1996;17:1373-1380.
41. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2004;145:239-247.
42. Baron JH, Moiseeva EP, de Bono DP, Abrams KR, Gershlick AM. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3-Fab (abciximab): A possible mechanism for influencing restenosis. Cardiovasc Res 2000;48:464-472.
43. 3 integrins. Circulation 1998;98:1085-1091.
44. 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 1996;93:2482-2487.
45. 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995;95:713-724.
46. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery. Circ Res 1985;56:139-145.
47. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reiley TM, Holmes DR Jr, Schwartz RS, Mousa SA. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary artery stent injury: Evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997;36:408-428.
48. Clarke S, Davies MC, Roberts CJ, Tendler SJB, Williams PM, O'Byrne V, Lewis AL, Russell J. The surface mobility of 2-methacryloytoxyethyl phosphorycholine-colauryl methacrylate polymers. Langmuir 2000;16:5116-5122.
49. Greisler HP, Cabusao EB, Lam TM, Ellinger J, Kim DU. Kinetics of collagen deposition with bioresorbable and non resorbable vascular prostheses. ASAIO Trans 1991;37:M472-MM475.
50. Bürger CM, Grabow N, Sternberg K, Ketner L, Kröger C, Lorenzen B, Hauenstein K, Schmitz KP, Kreutzer HJ, Lootz D, Ince H, Nienaber CA, Klar E, Schareck W. Iliac anastomotic stenting with a biodegradable poly-L- lactide stent: A preliminary study after 1 and 6 weeks. J Endovasc Ther 2006;13:539-548.
51. Kahn J. Drug Eluting stents and late events, a picture begins to emerge. Proc Transcathet Cardiovasc Ther 2006;3:2-5.
52. Shuchman M. Trading restenosis for thrombosis? New questions about drug eluting stents. New Engl J Med 2006;355:1949-1952.
53. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, Van Dahl J, Bosserhoff A-K, Michaeli W, Hanrath P, Weber C, Blindt R. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004;25:1330-1340.
54. Meng B Wang, XH, Cui FZ, Dong HY, Yu F. A new method of heparinizing PLLA film by surface entrapment. J Bioact Compat Polym 2004;19:131-143.
55. Iwasaki Y, Tojo Y, Kurosaki T, Nakabayashi N. Reduced adhesion of blood cells to biodegradable polymers by introducing phorphorylcholine moities. J Biomed Mater Res A 2003;65:164-169.
56. Mongrain R, Leask R, Brunette J, Faik I, Bulmen-Fleming N, Nguyen T. Numerical modeling of coronary drug eluting stents. Stud Health Technol Inform 2005;113:443-458.
57. Hwang C-W, Wu D, Edelman ER. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Interv 2003;5:7-12.
58. Levin AD, Jonas M, Hwang C-W, Edelman ER. Local and systemic drug competition in drug-eluting stent tissue deposition properties. J Control Release 2005;109:236-243.
59. Sakharov DV, Kalachev LV, Rijken DC. Numerical simulation of local pharmacokinetics of a drug after intravascular delivery with an eluting stent. J Drug Target 2002;10:507-513.